semaglutide for heart disease: may reduce risk by up to 20% in 6 months Obesity drug brings heart health

Is MOTS-c FDA Approved

doi: 10.3389/fonc.2025.1576781 Received 14 February 2025 Accepted 16 June 2025 Published 27 June 2025 Volume 15 - 2025 Edited by Sandip Patil, Shenzhen Childrens Hospital, China Reviewed by Francesco Grignani, University of Perugia, Italy Barbara A Osborne, University of Massachusetts Amherst, United States Katia Carneiro, Federal University of Rio de Janeiro, Brazil Madduri Srinivasarao, Purdue University, United States Updates Copyright 2025 Tian, Han, Song, Liu, Shen and Zhong

At $399 per month for standard semaglutide, more affordable options exist

The slower onset with injection lessens the immediate threat of acute respiratory depression (57)